Share-based Payment Arrangement, Expense in USD of Eiger BioPharmaceuticals, Inc. from 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Eiger BioPharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2012 to Q4 2023.
  • Eiger BioPharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2023 was $683K, a 62.9% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2023 was $5.01M, a 39.8% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5.01M, a 39.8% decline from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8.32M, a 5.27% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7.9M, a 32.3% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Eiger BioPharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 $5.01M $683K -$1.16M -62.9% 01 Oct 2023 31 Dec 2023 10-K 08 Apr 2024
Q3 2023 $6.17M $1.04M -$1.18M -53.3% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023
Q2 2023 $7.35M $745K -$1.46M -66.3% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 $8.81M $2.54M +$495K +24.2% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q4 2022 $8.32M $1.84M -$124K -6.31% 01 Oct 2022 31 Dec 2022 10-K 08 Apr 2024
Q3 2022 $8.44M $2.22M -$108K -4.64% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 $8.55M $2.21M +$150K +7.29% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $8.4M $2.05M +$498K +32.2% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 $7.9M $1.96M +$527K +36.7% 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023
Q3 2021 $7.37M $2.33M +$885K +61.2% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 $6.49M $2.06M +$596K +40.8% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 $5.89M $1.55M -$80K -4.91% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 $5.97M $1.44M +$89K +6.6% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2023
Q3 2020 $5.88M $1.45M -$204K -12.4% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 $6.09M $1.46M -$25K -1.68% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $6.11M $1.63M +$434K +36.3% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 $5.68M $1.35M -$163K -10.8% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2022
Q3 2019 $5.84M $1.65M +$477K +40.7% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 $5.37M $1.49M +$166K +12.6% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 $5.2M $1.2M +$192K +19.1% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 $5.01M $1.51M +$491K +48.1% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2021
Q3 2018 $4.52M $1.17M +$219K +23% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 $4.3M $1.32M +$375K +39.6% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 $3.92M $1M -$321K -24.2% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 $4.24M $1.02M -$418K -29.1% 01 Oct 2017 31 Dec 2017 10-K 13 Mar 2020
Q3 2017 $4.66M $953K -$287K -23.1% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 $4.95M $946K +$772K +444% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018
Q1 2017 $4.18M $1.32M +$986K +292% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018
Q4 2016 $3.19M $1.44M +$1.28M +828% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2019
Q3 2016 $1.91M $1.24M +$1.22M +5536% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 $689K $174K +$127K +270% 01 Apr 2016 30 Jun 2016 10-Q 11 Aug 2017
Q1 2016 $562K $338K +$335K +11167% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017
Q4 2015 $227K $155K +$2.31M 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2018
Q3 2015 -$2.08M $22K -$889K -97.6% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016
Q2 2015 -$1.19M $47K -$701K -93.7% 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016
Q1 2015 -$489K $3K -$516K -99.4% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q4 2014 $27K -$2.15M -$1.13M -111% 01 Oct 2014 31 Dec 2014 10-K 23 Mar 2017
Q3 2014 $1.16M $911K +$99K +12.2% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2014
Q2 2014 $1.06M $748K +$561K +300% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015
Q1 2014 $501K $519K +$440K +557% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q4 2013 $60.7K -$1.02M 01 Oct 2013 31 Dec 2013 8-K/A 17 Jun 2016
Q3 2013 $812K 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014
Q2 2013 $187K 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 $79K 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014

Eiger BioPharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $5.01M -$3.31M -39.8% 01 Jan 2023 31 Dec 2023 10-K 08 Apr 2024
2022 $8.32M +$416K +5.27% 01 Jan 2022 31 Dec 2022 10-K 08 Apr 2024
2021 $7.9M +$1.93M +32.3% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023
2020 $5.97M +$294K +5.18% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2023
2019 $5.68M +$672K +13.4% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022
2018 $5.01M +$764K +18% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021
2017 $4.24M +$1.05M +33% 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2020
2016 $3.19M +$2.96M +1305% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019
2015 $227K +$200K +741% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018
2014 $27K -$33.7K -55.5% 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2017
2013 $60.7K -$237K -79.6% 01 Jan 2013 31 Dec 2013 8-K/A 17 Jun 2016
2012 $298K 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.